Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464301 | 0.91 | MAPT (0.61) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8983901 | 0.83 | HRH3 (0.66) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2467838 | 0.83 | ACHE (0.56) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2467096 | 0.83 | HRH3 (0.69) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2469188 | 0.82 | HRH3 (0.70) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7044938 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL7044951 | 0.81 | XDH (0.56) | ALDH1A1RAB9ANPC1KDM4EMEN1 | |
| SCHEMBL7042817 | 0.80 | SIGMAR1 (0.59) | — | |
| SCHEMBL7044607 | 0.77 | ALDH1A1 (0.59) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2465863 | 0.77 | MAOB (0.53) | ALDH1A1RAB9ANPC1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608089-B2 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2003-08-19 | — | — | US | claimed |
| EP-1212312-B1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA SPA (IT) | 2003-04-02 | — | — | EP | claimed |
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2002-12-05 | — | — | US | claimed |
| US-6608089-B2 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2003-08-19 | — | — | US | disclosed |
| EP-1212312-B1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA SPA (IT) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2002-12-05 | — | — | US | disclosed |
| EP-1212312-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017985-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | BRCA1, NCEH1, EZH1 | ALDH1A1 2996/4885MAPT 3858/4885RAB9A 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.